HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC Receivables

The Accounts Receivable of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 3, 2026 is 124.10 B VND. In the previous year, Accounts Receivable was 87.35 B VND — a change of 42.07% (higher).

Receivables

124.10 BVND

YoY

42.07%

Last updated:

Accounts Receivable of HaTay Pharmaceutical JSC is 2024 124.10 B VND. Accounts Receivable of HaTay Pharmaceutical JSC was 2023 87.35 B VND. It decreases by 42.07% higher compared to the previous year.

The HaTay Pharmaceutical JSC Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
86.94 B VND
Jan 1, 2018
87.09 B VND
Jan 1, 2019
186.49 B VND
Jan 1, 2020
249.86 B VND
Jan 1, 2021
121.11 B VND
Jan 1, 2022
109.92 B VND
Jan 1, 2023
87.35 B VND
Jan 1, 2024
124.10 B VND
The HaTay Pharmaceutical JSC Receivables history
YEARReceivablesYoY
124.10 BVND+42.07%
87.35 BVND-20.53%
109.92 BVND-9.25%
121.11 BVND-51.53%
249.86 BVND+33.98%
186.49 BVND+114.12%
87.09 BVND+0.17%
86.94 BVND+12.63%
77.19 BVND-14.29%
90.06 BVND+32.59%
67.93 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

Accounts Receivable of HaTay Pharmaceutical JSC is 124.10 B VND in 2024.

Accounts Receivable of HaTay Pharmaceutical JSC changed from 87.35 B VND to 124.10 B VND, representing a 42.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's HaTay Pharmaceutical JSC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — HaTay Pharmaceutical JSC

All Key Metrics — HaTay Pharmaceutical JSC